Published on : Jun 06, 2016
ALBANY, New York, June 06, 2016: ResearchMoz.us has announced the addition of the “Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2022” report to its offering. The report is collated by conducting both primary as well as secondary research. This study presents an in-depth understanding of the clinical and commercial landscape of the market for acute heart failure. It also presents the diagnosis, prognosis, pathogenesis, and treatment available in the market at every stage of the disease. It collates comprehensive information on the therapeutics under development for acute heart failure. The study also provides information about the pharmacological action of the major therapeutics in the market and their complete development history.
The introduction section of the report encapsulates an overview of the market for acute heart failure and presents the global size of this market in 2015 and 2022. As per the report, the global acute heart failure market was pegged at US$188 mn in 2015 and is predicted to touch $929 mn by 2020, expanding at a healthy CAGR of 17.0% between 2015 and 2022. The disease overview section comes next in the report. Under this section, the physiology, etiology, disease management, symptoms, diagnosis, and the present treatment options for the disease have been highlighted.
Heart failure takes place when the heart isn’t able to pump enough blood to meet the demand of the human body. Heart failure can be chronic or acute. Chronic heart failure take place gradually over a period of time, while acute failure refers to a sudden failure of the heart. Acute heart failure majorly comprises the symptoms of peripheral perfusion or pulmonary congestion owing to vascular or cardiac dysfunction. Thus, acute heart failure is accompanied by symptoms of heart failure requiring immediate intervention.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=720128
The following section of the report presents the number of hospitalized cases having acute heart failure in the seven major markets i.e. Japan, the U.S, and the EU5 countries, namely Germany, France, Italy, Spain, and the UK, in the forecast horizon. The conventional therapies utilized for the management of acute heart failure in case of pulmonary edema, cardiogenic shock, hypotension, and hypertension have also been elaborated upon in this section. The current treatment options and novel therapies utilized in the market for acute heart failure have also been presented. Amongst the treatment options, loop diuretics emerged as the majorly utilized treatment option for acute heart failure in patients having dyspnoea caused by pulmonary edema.
The utilization of Carperitide in the treatment of acute heart failure has also been covered in this study. In this section, key attributes such as the disadvantages and advantages of using Carperitide, its product profile, and the cost of therapy have also been highlighted. The expected sale of drugs for acute heart failure in the forecast period is also detailed in this part of the report. The expansion of the acute heart failure market in the seven major markets and the treatment options utilized in these markets in the forecast period have also been included in the report. The report concludes by providing insights into the emerging therapies in the market, the unmet needs, and product development activities of the major players dominant in the market. Some of these key players are Bristol-Myers Squibb, Trevena, and Capricor Therapeutics, among others.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org